Form 4: Cytokinetics Director Edward M. Kaye Acquires Shares in Lieu of Cash Retainer
SEC Form 4 Filing
Director Edward M. Kaye acquired 255 shares of Cytokinetics Inc. common stock at $48.93 per share on January 2, 2025, through the Director Stock in Lieu of Cash Retainer Program.
Summary
- On January 2, 2025, Edward M. Kaye, a director of Cytokinetics Inc., acquired 255 shares of common stock.
- The acquisition was made through the Director Stock in Lieu of Cash Retainer Program.
- The price per share was $48.93.
- Following the transaction, Dr. Kaye beneficially owns 25,637 shares of Cytokinetics Inc.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. A director acquiring shares indicates confidence, but it's a small transaction related to compensation.
Positives
- The director's participation in the stock in lieu of cash retainer program demonstrates confidence in the company's future.
Industry Context
Directors receiving stock in lieu of cash compensation is a common practice to align their interests with shareholders and conserve company cash.
Stakeholder Impact
- The transaction could have a slightly positive impact on shareholders as it aligns the director's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Edward M. Kaye acquired 255 shares of Cytokinetics Inc. common stock. |
| 01/06/2025 | Date of signature by attorney-in-fact for Dr. Kaye. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.